Lupin Pharmaceuticals Inc. is recalling 7,872 bottles of Rifampin (rifampin) Capsules, 150 mg, because an impurity called 1-Methyl-4-Nitroso Piperazine (MNP) was detected during testing. These capsules are a prescription medication used to treat tuberculosis and other bacterial infections. The affected 30-count bottles were distributed to pharmacies across the country. No injuries or adverse incidents have been reported in connection with this recall.
The impurity MNP is a type of nitrosamine that may increase the risk of cancer if people are exposed to it above acceptable levels over long periods of time. Patients should consult their doctor before stopping this medication, as the risks of untreated tuberculosis or infection may outweigh the risk of the impurity.
You have 2 options:
Recall #: D-1343-2022. Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.